• Explore /
  • Poster
  • / Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.

Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.

Abstract Video & Slides Poster

Authors

null

Neal D. Shore

Carolina Urologic Research Center, Myrtle Beach, SC

Neal D. Shore , Noel Clarke , Andrew J. Armstrong , Mototsugu Oya , Giuseppe Procopio , João Daniel Cardoso Guedes , Cagatay Arslan , Niven Mehra , Emma Brown , Friederike Schlürmann , Jae Young Joung , Mikio Sugimoto , Karina Vianna , Christian Hosius , Alan Barnicle , Yu-Zhen Liu , Elizabeth Harrington , David McGuinness , Paula Michelle del Rosario , Fred Saad

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03732820

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 165)

DOI

10.1200/JCO.2024.42.4_suppl.165

Abstract #

165

Poster Bd #

G15

Abstract Disclosures

Similar Posters

First Author: Elena Castro

First Author: Johann S. De Bono

First Author: Daniel Triner

First Author: Neal D. Shore